AU3357299A - Use of dipeptidyl peptidase (dpp4) for suppressing the malignant phenotype of cancer cells - Google Patents

Use of dipeptidyl peptidase (dpp4) for suppressing the malignant phenotype of cancer cells

Info

Publication number
AU3357299A
AU3357299A AU33572/99A AU3357299A AU3357299A AU 3357299 A AU3357299 A AU 3357299A AU 33572/99 A AU33572/99 A AU 33572/99A AU 3357299 A AU3357299 A AU 3357299A AU 3357299 A AU3357299 A AU 3357299A
Authority
AU
Australia
Prior art keywords
dpp4
suppressing
cancer cells
dipeptidyl peptidase
malignant phenotype
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU33572/99A
Inventor
Alan N. Houghton
Umadevi V. Wesley
Jedd D. Wolchok
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Sloan Kettering Institute for Cancer Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sloan Kettering Institute for Cancer Research filed Critical Sloan Kettering Institute for Cancer Research
Publication of AU3357299A publication Critical patent/AU3357299A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU33572/99A 1998-03-20 1999-03-19 Use of dipeptidyl peptidase (dpp4) for suppressing the malignant phenotype of cancer cells Abandoned AU3357299A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7880698P 1998-03-20 1998-03-20
US60078806 1998-03-20
PCT/US1999/005918 WO1999047152A2 (en) 1998-03-20 1999-03-19 Use of dipeptidyl peptidase (dpp4) of fibroblast activating protein alpha for suppressing the malignant phenotype of cancer cells

Publications (1)

Publication Number Publication Date
AU3357299A true AU3357299A (en) 1999-10-11

Family

ID=22146339

Family Applications (1)

Application Number Title Priority Date Filing Date
AU33572/99A Abandoned AU3357299A (en) 1998-03-20 1999-03-19 Use of dipeptidyl peptidase (dpp4) for suppressing the malignant phenotype of cancer cells

Country Status (2)

Country Link
AU (1) AU3357299A (en)
WO (1) WO1999047152A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6890904B1 (en) 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
US6709651B2 (en) 2001-07-03 2004-03-23 B.M.R.A. Corporation B.V. Treatment of substance P-related disorders
WO2004045497A2 (en) * 2002-05-17 2004-06-03 Board Of Regents, The University Of Texas System Cd26-based therapies for cancers and immune disease
US7241581B2 (en) * 2002-08-16 2007-07-10 Rigel Pharmaceuticals, Inc. Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a c-MYC protein
WO2005071073A1 (en) * 2004-01-09 2005-08-04 Point Therapeutics, Inc. Fap compositions and the use thereof for immunomodulation
US20080171033A1 (en) * 2004-08-26 2008-07-17 Chiwen Chang Compositions and methods for treating diseases associated with angiogenesis and inflammation
DK1942898T4 (en) 2005-09-14 2014-06-02 Takeda Pharmaceutical Dipeptidyl peptidase inhibitors for the treatment of diabetes
CN100344325C (en) * 2005-10-17 2007-10-24 华南师范大学 Medicine for treating cervical cancer and preparation method and application thereof
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2008011482A2 (en) * 2006-07-19 2008-01-24 Genentech, Inc. Methods and compositions for the diagnosis and treatment of cancer
WO2009109927A2 (en) * 2008-03-05 2009-09-11 Tel Hashomer Medical Research Infrastructure And Services Ltd. Glp-1 receptor agonists and related active pharmaceutical ingredients for treatment of cancer
ES2972577T3 (en) 2016-12-14 2024-06-13 Purdue Research Foundation Imaging and therapy targeting fibroblast activation protein (FAP)

Also Published As

Publication number Publication date
WO1999047152A2 (en) 1999-09-23
WO1999047152A3 (en) 2000-01-27

Similar Documents

Publication Publication Date Title
HUP0102001A3 (en) New dipeptidyl peptidase iv effectors
AU3546400A (en) Tandem immuno-assay for cancer
PL345060A1 (en) Compounds of unstable dipeptidyl peptidase iv inhibitors
NZ334034A (en) Use of a melanoma differentiation associated gene (mda-7) for reversing a cancerous phenotype
AU5170900A (en) Cell proliferation inhibitors
AU2002340139A1 (en) Inhibitors of the egf receptor for the treatment of thyroid cancer
EP1176964B8 (en) Uses of et743 for treating cancer
AU3357299A (en) Use of dipeptidyl peptidase (dpp4) for suppressing the malignant phenotype of cancer cells
AU2879300A (en) Methods for anti-tumor therapy
HK1028350A1 (en) Leptin as an inhibitor of tumor cell proliferation.
AU2002308522A1 (en) Methods for inhibiting tumor cell proliferation
AU3528400A (en) Apoptosis related genes
AU2723099A (en) Tryptase inhibitors
AU5928599A (en) Methods for treating cell proliferative disorders including cancer
AU2002341749A1 (en) Methods and compositions for inhibiting the proliferation of prostate cancer cells
AU4697600A (en) Methods for increasing t cell proliferation
AU7363000A (en) Method for reducing the risk of cancer
AU1916601A (en) Oncolytic combinations for the treatment of cancer
AU1916501A (en) Oncolytic combinations for the treatment of cancer
AU1917101A (en) Oncolytic combinations for the treatment of cancer
AU1595001A (en) Oncolytic combinations for the treatment of cancer
AU7854400A (en) Gestational agents which modulate cell proliferation
AU2002234591A1 (en) Inhibitors of the e2f-1/cyclin interaction for cancer therapy
AU1595101A (en) Oncolytic combinations for the treatment of cancer
AU3459497A (en) Cancer cell proliferation inhibitors

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase